Biologic Therapies Summit
‘So much misinformation’: Opioid use in chronic pain informed by persistent myths
Popular myths continue to influence the way physicians and patients alike think about and engage with chronic pain and the use of opioids, according to a speaker at the 2023 Biologic Therapies Summit.
CAR-T cell therapy, recent approvals put precision medicine ‘on the horizon’ for lupus
The recent success of chimeric antigen receptor-T cell therapy, along with three high-profile FDA approvals, may help make precision medicine a reality in lupus, according to a presenter at the Biologic Therapies Summit.
‘It takes a village’ to manage cardiovascular disease in patients with IMIDs
Properly managing cardiovascular disease in patients with immune-mediated inflammatory diseases requires following guidelines and inter-specialty collaboration, according to a speaker at the Biologic Therapies Summit.
‘A ton of hurdles’ stand in the way of precision medicine for rheumatoid arthritis
The slow march toward precision medicine in rheumatoid arthritis features increased use of serum biomarkers and novel approaches to biopsy, but “a ton of hurdles” remain, according to a presenter at the Biologic Therapies Summit.
To understand long COVID’s pathogenesis, consider fibromyalgia
The current understanding of long COVID’s pathogenesis may be better served by looking to other diseases and syndromes, particularly fibromyalgia, according to a speaker at the 2023 Biologic Therapies Summit.
Additional COVID-19 vaccine doses may ‘bully’ response in immunosuppressed patients
Additional COVID-19 vaccine doses can occasionally “bully” a humoral response in patients who are immunocompromised, according to a presenter at the 2023 Biologic Therapies Summit.
More JAK inhibitors ‘coming down the pike’ despite poor understanding of mechanism
The pipeline of Janus kinase inhibitors is robust even as researchers struggle to fully understand how they work, according to a presenter at the 2023 Biologic Therapies Summit.
High-dose flu vaccines among the immunocompromised: ‘Not just for people older than 65’
All immunocompromised adults should receive the high-dose formulation of the influenza vaccine, according to a presenter at the Biologic Therapies Summit.
End of COVID emergency marks ‘less government effort,’ greater role for rheumatologists
Communication between rheumatologists and patients with immune-mediated conditions will be essential for navigating COVID-19 in the endemic phase, according to a presenter at the Biologic Therapies Summit.
Alternative complement pathway inhibition may be key to lupus management
The next therapeutic innovation in complement biology therapies for rheumatic diseases may involve inhibiting the alternative complement pathway, according to a speaker at the Biologic Therapies Summit.